1. Scrip
  2. >>Business

US Pricing Pressure Spotlights Regulatory Compliance As Key To Indian Companies’ Performance

Countering Strategies In Play

 
• By Vibha Ravi

While generic drug prices continued to erode in the US during the second quarter of FY23, compliance will be key to the performance of Indian firms such as Torrent and Jubilant through the rest of the year. The US FDA has issued multiple observations in 2022, but an import alert for Glenmark’s Baddi unit is the harshest so far.

FDA Approved
FDA's Moves Will Have Greater Impact On Financial Performance • Source: Shutterstock

Indian companies saw continued erosion of generic drug prices in the US during the second quarter of fiscal year 2023, which ends 31 March, management commentary from companies which have announced earnings so far indicates.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Gilead Keeping Eye On Policy But Sees Little Impact From HHS Cuts, Tariffs

 
• By Alaric DeArment

The drugmaker said in its first quarter earnings that it did not foresee negative effects on potential approval and launch of lenacapavir for PrEP later this year.

Merck Forecast Incorporates $200m Tariff Hit

 
• By Joseph Haas

On a quarterly earnings call that touched on Trump administration policy impacts, Merck said it is well positioned for changes coming from the new administration.

BMS Keeping A Watchful Eye On Tariffs, Pricing And Other Policy Changes

 
• By Mandy Jackson

Bristol Myers Squibb’s first quarter revenue beat consensus and the company raised its 2025 guidance, even when including the impact of Chinese tariffs on US products.

More from Scrip

In Brief: Bioxodes To Take Novel Hemorrhagic Stroke Drug Into Registrational Trial

 
• By Sushmita Panda

The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

Roche Moves To Soften Tariff Blow But Admits M&A Dealmaking Could Be Hit

 
• By Andrew McConaghie

Roche believes it can ride out any short-term effects of US tariffs if they are imposed but wants to see reform of US and European pricing to help support the sector.